Cabaletta Bio, Inc. Files 8-K

Ticker: CABA · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1759138

Sentiment: neutral

Topics: corporate-filing, 8-K

Related Tickers: CABA

TL;DR

CABA filed an 8-K, confirming HQ address and Nasdaq listing.

AI Summary

Cabaletta Bio, Inc. filed an 8-K on October 9, 2025, to report current information. The filing confirms the company's principal executive offices are located at 2929 Arch Street, Suite 600, Philadelphia, Pennsylvania, 19104. Cabaletta Bio's common stock trades on The Nasdaq Global Select Market under the ticker symbol CABA.

Why It Matters

This 8-K filing serves as a routine update for investors, confirming the company's official address and stock exchange listing.

Risk Assessment

Risk Level: low — This is a routine filing that does not contain new material financial or operational information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Cabaletta Bio, Inc.?

The primary purpose of this 8-K filing is to report current information as required by the Securities Exchange Act of 1934, specifically confirming the company's principal executive offices and stock listing.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on October 09, 2025.

Where are Cabaletta Bio, Inc.'s principal executive offices located?

Cabaletta Bio, Inc.'s principal executive offices are located at 2929 Arch Street, Suite 600, Philadelphia, Pennsylvania, 19104.

On which stock exchange is Cabaletta Bio, Inc.'s common stock traded?

Cabaletta Bio, Inc.'s common stock is traded on The Nasdaq Global Select Market.

What is the trading symbol for Cabaletta Bio, Inc.'s common stock?

The trading symbol for Cabaletta Bio, Inc.'s common stock is CABA.

Filing Stats: 998 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2025-10-09 12:03:05

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 9, 2025, Cabaletta Bio, Inc. ("Cabaletta" or the "Company") issued a press release reporting new clinical and translational data from the ongoing RESET-PV trial evaluating rese-cel (resecabtagene autoleucel, formerly known as CABA-201) (the "Press Release"). A copy of the Press Release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On October 9, 2025, the Company posted to the "Investors & Media" section of the Company's website at www.cabalettabio.com an updated corporate presentation (the "Corporate Presentation"). A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. Cabaletta is presenting new clinical and translational data from three evaluable patients who were dosed with rese-cel in the RESET-PV trial in a late-breaking clinical oral presentation at the 2025 European Society of Gene & Cell Therapy (ESGCT) Annual Congress. The RESET-PV trial is the first study within Cabaletta's RESET clinical development program to evaluate rese-cel without the use of cyclophosphamide and fludarabine as preconditioning agents. Key clinical and translational insights from these patients, as of the data cut-off date of September 11, 2025, include: Translational Profile: Rese-cel exhibited similar CAR T cell expansion and contraction kinetics relative to translational data reported from other RESET trials with preconditioning. All three patients experienced substantial depletion of B cells within the first month post-infusion, with patients 2 and 3 achieving complete peripheral B cell depletion. In these two patients, rapid reduction in autoantibodies to desmoglein was observed and the increase in peak B cell activating factor (BAFF) was within the range of patients dosed with rese-cel plus preconditioning from pre-infusion through the latest follow-up, suggestive of deep B cell depletion in the tissue. Safety Profile: Rese-cel was generally well tolerated with no immune effector cell-associated neurotoxicity syndrome (ICANS) reported. After infusion, patient 1 experienced transient fever (grade 1 cytokine release syndrome). Patient 2 required a course of steroids for a disease flare in the first two weeks following infusion after discontinuing immunomodulators. This steroid course w

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by the registrant on October 9, 2025, furnished herewith. 99.2 Cabaletta Bio, Inc. Corporate Presentation, dated October 2025, filed herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CABALETTA BIO, INC. Date: October 9, 2025 By: /s/ Steven Nichtberger Steven Nichtberger Chief Executive Officer and President (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing